The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?
Recurrence Score testing does not appear to benefit patients with grade 1, progesterone receptor positive breast cancers: An opportunity to eliminate over-treatment and decrease testing costs.